Patents Issued in September 4, 2018
-
Patent number: 10064814Abstract: The use of spider venom, molecules or synthetic analogs thereof for skin whitening. Also, compositions that include spider venom, molecules or synthetic analogs thereof for skin whitening/depigmenting, and a non-therapeutic method for whitening human skin that includes topically applying an effective amount on human skin of the composition.Type: GrantFiled: September 5, 2013Date of Patent: September 4, 2018Assignees: LABORATOIRE IN'OYA, LATOXAN, UNIVERSITE AIX-MARSEILLEInventors: Kamel Mabrouk, Jose Luis, Harold De Pomyers, Denis Bertin, Abd Haq Bengeloune, Marion Verdoni, Didier Gigmes, Hermine Roudaut
-
Patent number: 10064815Abstract: The subject matter of the present invention is pertinent to the field of vaginal delivery of pharmaceutically active agents. Embodiments of the instant invention disclose methods for treating a variety of progesterone related disorders by vaginal administration of a pullulan capsule and a fill formulation comprising one or more antiprogestins dispersed in a mixture of isopropyl palmitate or isopropyl myristate and a polyethylene glycol.Type: GrantFiled: April 22, 2015Date of Patent: September 4, 2018Inventors: Joseph S. Podolski, Kuang Hsu
-
Patent number: 10064816Abstract: Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using topical application of a therapeutic agent such as an alpha-1 adrenergic receptor agonist to the nipple-areola complex are disclosed.Type: GrantFiled: June 10, 2016Date of Patent: September 4, 2018Assignee: RejoyInventors: Ofer A. Goren, John McCoy
-
Patent number: 10064817Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.Type: GrantFiled: October 28, 2011Date of Patent: September 4, 2018Assignee: Meda Pharmaceuticals Inc.Inventors: Phuong Grace Dang, Brian D. Lawrence, Gul Balwani, Alexander D. D'Addio
-
Patent number: 10064818Abstract: The invention provides compositions and methods for the treatment of presbyopia. In a preferred embodiment correction of presbyopia occurs without reduction in distance vision acuity. The compositions of the invention preferably contain pilocarpine and tropicamide.Type: GrantFiled: September 22, 2015Date of Patent: September 4, 2018Assignee: PRESBYOPIA THERAPIES, LLCInventors: Gerald Horn, Lee Nordan
-
Patent number: 10064819Abstract: Devices, systems, and methods for delivery of an active agent into the eye of a subject can include an intraocular active agent delivery device including an active agent dispersed within a biodegradable active agent matrix. The active agent includes dexamethasone and the delivery device is adapted to fit within a lens capsule or ciliary sulcus of an eye. The delivery device can be inserted into the lens capsule or ciliary sulcus of an eye during cataract surgery or for treatment of uveitis.Type: GrantFiled: July 6, 2012Date of Patent: September 4, 2018Assignee: University of Utah Research FoundationInventors: Balamurali K. Ambati, Bruce K. Gale, Srinivas Rao Chennamaneni
-
Patent number: 10064820Abstract: Combinations of a first generation antihistamine for a quick onset with a maintenance dosage amount of a second or third generation antihistamine, along with an additional active agent such as a decongestant, a cough suppressant (an antitussive), a leukotriene receptor antagonist, a 5-lipoxygenase inhibitor, a bronchodilator, an expectorant, or a combination thereof, are disclosed. Methods of using such combinations by concomitant administration, either in the form of a single composition or multiple compositions, are further disclosed.Type: GrantFiled: September 30, 2016Date of Patent: September 4, 2018Assignee: APTAPHARMA INC.Inventors: Siva Rama K. Nutalapati, Prahlad Patel, Nisha Sureshbhai Patel
-
Patent number: 10064821Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.Type: GrantFiled: June 27, 2017Date of Patent: September 4, 2018Assignee: EP Pharma, LLCInventors: Charles Raymond Eck, Christopher L. Pelloni
-
Patent number: 10064822Abstract: The present disclosure relates to a polypeptide based block copolymer having biodegradability due to peptidase, and a process for the preparation thereof, and polymer micelles using the same. The block copolymer according to the present disclosure is a block copolymer of a polyethylene glycol-based compound having properties such that the solubility for water is different depending on the pH, but cannot form micelles due to a self-assembly phenomenon; and a polyglutamic acid-based compound formed using an aminolysis reaction of glutamic acid and tertiary amine in which the end of one alkyl group is substituted with NH2, or using an aminolysis reaction of glutamic acid and triamine. The block copolymer of the present disclosure has advantages in that the block polymer has both pH sensitivity and biodegradability due to peptidase in the body, and thereby a degradation rate related to a drug release cycle is controlled.Type: GrantFiled: October 6, 2015Date of Patent: September 4, 2018Assignee: Research & Business Foundation Sungkyunkwan UniversityInventors: Doo Sung Lee, Yi Li, Bong Sup Kim
-
Patent number: 10064823Abstract: In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.Type: GrantFiled: August 22, 2016Date of Patent: September 4, 2018Assignee: Veiled Therapeutics LLCInventors: James D. McChesney, Igor Nikoulin, Steve J. Bannister, Douglas L. Rodenburg
-
Patent number: 10064824Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: GrantFiled: February 9, 2016Date of Patent: September 4, 2018Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Patent number: 10064825Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: GrantFiled: September 12, 2017Date of Patent: September 4, 2018Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Patent number: 10064826Abstract: The invention provides a process for preparing stable, high API content, solid pharmaceutical dosage forms by direct compression or dry granulation, characterized in that the pharmaceutical tablets rapidly disintegrate in water or other aqueous solutions to produce a clear or almost clear solution. Also provided is a pharmaceutical carglumic acid tablet, which has improved manufacturing, dissolution, and stability properties, and is less expensive to produce, compared to the equivalent commercial product.Type: GrantFiled: March 14, 2014Date of Patent: September 4, 2018Assignee: Navinta, LLCInventors: Sanjay Rangnathrao Kawale, Mahendra R. Patel
-
Patent number: 10064827Abstract: The invention relates to a method for producing a molded piece (compression molding, molded body) using a compression molding device. The use of special construction features for the compression molding device, such as a spring-loaded punch, an intermediate punch and clamps, allows the advantageous production of molded pieces.Type: GrantFiled: December 11, 2014Date of Patent: September 4, 2018Inventor: Roland Saur-Brosch
-
Patent number: 10064828Abstract: The disclosure is directed to drug delivery devices that provide for combinations of extended and pulsed controlled release delivery of active pharmaceutical ingredient(s) APIs. The described drug delivery devices for oral administration of therapeutic compositions can include two or more populations of unit dosage forms including one or more API's in various combinations of pulsed and delayed/extended delivery formulations. The population of unit dosage forms are provided in a variety of different vehicles such as granules, beads, pellets, or tablets and can be contained within a drug delivery device of the present disclosure.Type: GrantFiled: December 23, 2005Date of Patent: September 4, 2018Assignee: INTELLIPHARMACEUTICS CORP.Inventors: Isa Odidi, Amina Odidi
-
Patent number: 10064829Abstract: Provided are heat-processed or heat-processible health food products beneficially affecting the consumer's intestinal microbial balance. The food products are particularly liquid-based products which comprise a probiotic component capable of resisting heat and humidity.Type: GrantFiled: April 19, 2014Date of Patent: September 4, 2018Assignee: DeGama Smart, Ltd.Inventor: Adel Penhasi
-
Patent number: 10064830Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. 20-23.Type: GrantFiled: May 25, 2017Date of Patent: September 4, 2018Inventors: Stanley L. Hazen, Bruce Levison, Zeneng Wang
-
Patent number: 10064831Abstract: Licochalcone A and/or plant extracts or microbiologically obtained extracts with an active content of Licochalcone A or cosmetic or dermatological preparations containing Licochalcone A and/or plant extracts or microbiologically obtained extracts with an active content of Licochalcone A for the care of the skin of patients of diabetes mellitus.Type: GrantFiled: February 8, 2016Date of Patent: September 4, 2018Assignee: BEIERSDORF AGInventors: Dennis Roggenkamp, Olga Reichert, Ludger Kolbe
-
Patent number: 10064832Abstract: The present invention relates to kartogenin-conjugated chitosan particles with an improved sustained release property and biocompatibility. Effects of increases in biocompatibility, chondrogenic differentiation efficiency and retention time in the joints were confirmed by using kartogenin-chitosan microparticles or kartogenin-chitosan nanoparticles of the present invention, and thus targeted treatment, in the prevention or treatment of bone diseases, is enabled through a more fundamental approach.Type: GrantFiled: August 11, 2015Date of Patent: September 4, 2018Assignee: DONGGUK UNIVERSITY INDUSTRY-ACADEMY COOPERATION FOUNDATIONInventors: Gun Il Im, Mi Lan Kang
-
Patent number: 10064833Abstract: Compositions (e.g., pharmaceutical compositions or nutraceutical compositions) comprising a benzoate compound and an excipient, wherein the excipient is tannic acid, and uses thereof for treating central nervous system disorders.Type: GrantFiled: July 20, 2017Date of Patent: September 4, 2018Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Ching-Hsun Huang, Ching-Cheng Wang, Tien-Lan Hsieh
-
Patent number: 10064834Abstract: The present invention includes a method of inhibiting or reducing mTOR signaling or inhibition of indoleamine dioxygenase-1 (IDO1) in a subject with a proliferative disease, which comprises administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: May 9, 2017Date of Patent: September 4, 2018Assignee: Texas Tech University SystemInventors: Vadivel Ganapathy, Yangzom D. Bhutia, Babu Ellappan, Sabarish Ramachandran
-
Patent number: 10064835Abstract: Disclosed is the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for use in a method of treating a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. 9. Also disclosed is the use of the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for the manufacture of a medicament for use in the treatment of a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. In certain embodiments, the combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine are orally administered via a nutritional composition.Type: GrantFiled: January 10, 2013Date of Patent: September 4, 2018Assignee: ABBOTT LABORATORIESInventors: Jeffrey L. Nelson, Anne C. Voss, Maria G. Baggs, Charles L. Paule, Refaat A. Hegazi, Fabrizis Suarez, Gary Fanjiang
-
Patent number: 10064836Abstract: Compositions and methods for treating parasitic infections are provided. The compositions can include two or more of alpha-pinene, linalyl acetate, para-cymene, and thymol octanoate. The compositions and methods can be effective against, for example, protozoan parasites, helminthic parasites, nematodes, trematodes, flukes, cestodes, and the like. Formulations made from the composition are also provided, including formulations in which the composition is combined with a carrier to form a food product and/or a drink. The formulation can be, for example, a suspension, a solution, or an emulsion in an oily or an aqueous carrier; likewise, the composition can be provided in an encapsulated or microencapsulated form.Type: GrantFiled: August 5, 2013Date of Patent: September 4, 2018Assignee: TyraTech, Inc.Inventors: Essam Enan, Ahmad Akashe, Anilkumar Gaonkar, Leslie West
-
Patent number: 10064837Abstract: The abietic acid derivatives as anti-tumor agents are derivatives of abietic acid in which the hydroxyl entity (—OH) of the carboxyl entity is replaced by an electronegative substituent, which may be C6H5-O—, C6H5-S—, or C6H5-NH—, and a hydrogen atom on one of the rings is replaced by a hydroxyl (—OH) substituents, the derivatives having the formula: wherein X is O, S, or NH. The derivatives are formed by formation of an intermediate lactone from abietic acid, followed by reaction of the lactone with phenol, thiophenol, or aniline. All of the derivatives exhibited potent 5?-reductase inhibitor activity, both in vitro and in vivo, and anti-tumor activity with regard to two prostate cancer cell lines—LNCaP and PC-3. The intermediate lactones are also derivatives of abietic acid that exhibit anti-tumor activity.Type: GrantFiled: February 15, 2018Date of Patent: September 4, 2018Assignee: KING SAUD UNIVERSITYInventors: Abd El-Galil E. Amr, Mohamed A. Al-Omar, Abdulrahman A. Almehizia
-
Patent number: 10064838Abstract: A method for treating tau-associated disease by administering a pharmaceutical composition comprising a tetrahydropyranol derivative to a subject in need is disclosed. Particularly, a method for treating Alzheimer's disease by administering a pharmaceutical composition comprising a tetrahydropyranol derivative to a subject in need is disclosed. The tetrahydropyranol derivatives have demonstrated their abilities for reducing tau aggregation.Type: GrantFiled: February 16, 2017Date of Patent: September 4, 2018Assignee: National Taiwan Normal UniversityInventors: Guey-Jen Lee-Chen, Kwun-Min Chen
-
Patent number: 10064839Abstract: The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2.Type: GrantFiled: December 20, 2016Date of Patent: September 4, 2018Assignee: Zafgen, Inc.Inventors: Thomas E. Hughes, James E. Vath
-
Patent number: 10064840Abstract: A pharmaceutical composition for the treatment of multi-drug resistant infections includes an antimicrobial agent in combination the benzopyrano[3,4-b][1]benzopyran-12(6H)-one class of compound boeravinone B of Formula 1: The bio-efficacy of anti-infective drugs can be potentiated, when used in combination with boeravinone B. Boeravinone B can overcome the resistance or multi-drug resistance developed by bacteria against quinolone, mupirocin and macrolide class of anti-bacterial agents via inhibition of bacterial efflux pumps. Thus, the compositions can be used to treat or prevent drug-resistant bacterial diseases.Type: GrantFiled: October 21, 2015Date of Patent: September 4, 2018Assignee: Council of Scientific & Industrial ResearchInventors: Ram Vishwakarma, Ajay Kumar, Inshad Ali Khan, Sandip Bibishan Bharate, Prashant Joshi, Samsher Singh, Naresh Satti
-
Patent number: 10064841Abstract: Isoandrographolide-19-propionate for treatment of non-alcoholic fatty liver disease (NALFD) relates to the compound isoandrographolide-19-propionate (IAN-19P), having the structural formula: and pharmaceutically acceptable salts thereof. The compound is synthesized by reaction of isoandrographolide with anhydrous propionic acid in the presence of N,N?-dicyclohexylcarbodiimide and 4-dimethylaminopyridine. In vitro testing shows that isoandrographolide-19-propionate has lower toxicity than andrographolide, but has significantly high activity at a concentration of 50 ?M. IAN-19P produced normal triglyceride levels and significantly lowered lipoperoxide formation in palmitate-oleate induced steatotic HepG2 cells, and also lowered ALT leakage from the treated cells.Type: GrantFiled: January 8, 2018Date of Patent: September 4, 2018Assignee: KING SAUD UNIVERSITYInventors: Naif Abdullah Al-Dhabi, Savarimuthu Ignacimuthu, P. Pandikumar, Erenius Toppo, Sylvester Darvin
-
Patent number: 10064842Abstract: The present disclosure relates to methods and compositions for modulating the activity of KCNQ channels as a means for reducing the effects of aberrant KCNQ channel function associated with epilepsy, deafness and arrhythmias including but not limited to, Long-QT syndrome (“LQTS”), and atrial fibrillation. The present disclosure also relates to the discovery of certain regions of KCNQ channels that interact with various channel stimulating molecules such as, ATP, and PIP2, as well as KCNQ channel domains that effect voltage dependant channel activation. The disclosure is also directed to the use of small molecules to modulate KCNQ channel activity in a cell. Moreover, the present disclosure relates to the therapeutic effects of treating a subject with modulators of KCNQ channel activity.Type: GrantFiled: April 25, 2016Date of Patent: September 4, 2018Assignees: WASHINGTON UNIVERSITY, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Jianmin Cui, Ira S. Cohen, Xiaoqin Zou
-
Patent number: 10064843Abstract: The present invention relates to a novel bis-amide derivative compound or a pharmaceutically acceptable salt thereof; a method of preparation thereof; and a pharmaceutical composition for preventing or treating diseases caused by hepatitis C virus infection and health functional food for preventing or ameliorating diseases caused by hepatitis C virus infection, containing the bis-amide derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient. The novel bis-amide derivative compound of the present invention, particularly WJCPA-126, specifically binds to the catalytic site of CypA to effectively inhibit the activity of an isomerase, and the duration of the inhibitory effect can be increased because WJCPA-126 binds to CypA with high binding affinity exhibiting a low dissociation rate (Koff). Accordingly, WJCPA-126 has nontoxic and non-immunosuppressive characteristics and can effectively inhibit HCV replication in vitro and in vivo model systems.Type: GrantFiled: September 5, 2014Date of Patent: September 4, 2018Assignee: University-Industry Cooperation Group of Kyung Hee UniversityInventors: Sung Soo Kim, Won Jea Cho
-
Patent number: 10064844Abstract: The present invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4?-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as medicaments.Type: GrantFiled: May 27, 2016Date of Patent: September 4, 2018Assignee: MEREO BIOPHARMA 2 LIMITEDInventors: Ann Taylor, Lloyd B. Klickstein, Jeewan Thakur
-
Patent number: 10064845Abstract: The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist.Type: GrantFiled: May 11, 2017Date of Patent: September 4, 2018Assignees: Cumberland Pharmaceuticals, Inc., Vanderbilt UniversityInventors: Leo Pavliv, James West, Ines Macias-Perez, Erica Carrier
-
Patent number: 10064846Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.Type: GrantFiled: August 28, 2017Date of Patent: September 4, 2018Assignee: vTv Therapeutics LLCInventors: Adnan M. M. Mjalli, Maria Carmen Valcarce Lopez
-
Patent number: 10064848Abstract: Compounds for the preparation of pyridone derivatives are provided. In particular, compounds of formula (IA) are provided, wherein the variable groups are as defined in the specification. The compounds of formula (IA) can be used as intermediates in the preparation of pyridone derivatives useful as mitogen-activated protein kinase kinase (MEK) inhibitors and therapeutic agents for treating cancer.Type: GrantFiled: September 28, 2017Date of Patent: September 4, 2018Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.Inventors: Wangyang Tu, Haitang Zhang, Guoji Xu, Jiangtao Chi
-
Patent number: 10064849Abstract: The invention relates to pharmaceutical compositions for direct systemic introduction, are also known as DSI pharmaceutical compositions, for used as human veterinary pharmaceutical compositions. In one embodiment, the invention relates to a pharmaceutical composition for direct system introduction comprising bovine gelatin, mannitol, an optional surfactant, an optional flavorant, and an active pharmaceutical ingredient. A DSI pharmaceutical composition of the invention has a disintegration time of 7 seconds or less in deionized water maintained at 37.0° C.±0.5° C. The invention also relates to a method of delivering an active pharmaceutical ingredient to an animal comprising the step of placing a DSI pharmaceutical composition of the invention into a mucosal cavity of an animal to be treated with the active pharmaceutical ingredient and to the corresponding methods of treatment.Type: GrantFiled: December 17, 2012Date of Patent: September 4, 2018Assignee: NEW MARKET PHARMACEUTICALSInventors: Mark Ridall, David Rock
-
Patent number: 10064850Abstract: The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behavior and relapse practice of an addictive behavior or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPAR?) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPAR? agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse.Type: GrantFiled: August 8, 2016Date of Patent: September 4, 2018Assignee: Omeros CorporationInventor: Roberto Ciccocioppo
-
Method for the treatment of neurological disorders by enhancing the activity of ?-glucocerebrosidase
Patent number: 10064851Abstract: Provided is a method of increasing the stability of wild-type ?-glucocerebrosidase. Also provided are methods of treating and/or preventing an individual having a neurological disease in which increased expression or activity of ?-glucocerebrosidase in the central nervous system would be beneficial. This method comprises administering an effective amount of a pharmacologic chaperone for ?-glucocerebrosidase, with the proviso that the individual does not have a mutation in the gene encoding ?-glucocerebrosidase. Further provided are ?-glucocerebrosidase inhibitors which have been identified as specific pharmacologic chaperones and which have been shown to increase activity of ?-glucocerebrosidase in vivo in the central nervous system.Type: GrantFiled: August 1, 2016Date of Patent: September 4, 2018Assignee: Amicus Therapeutics, Inc.Inventor: Brandon Alan Wustman -
Patent number: 10064852Abstract: Disclosed herein are methods for treating a human subject having a disease associated with an increased level of apoptosis using a nitroxide. Further disclosed are methods for treating a human subject in need of a reduced expression level of a gene associated with the apoptosis pathway using a nitroxide.Type: GrantFiled: January 19, 2017Date of Patent: September 4, 2018Inventor: Louis Habash
-
Patent number: 10064853Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI.Type: GrantFiled: June 26, 2017Date of Patent: September 4, 2018Assignees: Beth Israel Deaconess Medical Center, Inc., The Broad Institute, Inc.Inventors: Robert Flaumenhaft, Partha Pratim Nag, Tatiana Pilyugina, Jun Pu, Sivaraman Dandapani, Benito Munoz, Chris Dockendorff
-
Patent number: 10064854Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.Type: GrantFiled: September 19, 2017Date of Patent: September 4, 2018Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITEDInventors: Neil W. Johnson, Jiri Kasparec
-
Patent number: 10064855Abstract: Provided herein are composite nanoparticles, methods of making composite nanoparticles and methods of using composite nanoparticles to treat or ameliorate various diseases, such as, for example, cancer.Type: GrantFiled: March 8, 2017Date of Patent: September 4, 2018Assignee: Los Gatos Pharmaceuticals, Inc.Inventors: Peter Langecker, Matthias Steiert, Toshiaki Hino, Jan Scicinksi, Kumarapandian Paulvannan
-
Patent number: 10064856Abstract: Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.Type: GrantFiled: August 22, 2017Date of Patent: September 4, 2018Assignee: LOCAL PHARMA, INC.Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
-
Patent number: 10064857Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.Type: GrantFiled: August 30, 2017Date of Patent: September 4, 2018Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 10064858Abstract: The present invention provides methods and compositions for treating or preventing bacterial infections, where a pharmaceutically acceptable iron chelator that reduces biological availability of iron for one or more strains of bacteria, such as VK28 or an analog or derivative thereof is administered to a patient in need of treatment. The method also provides methods and compositions where an iron chelator and an antibiotic are administered to a patient in need of treatment for a bacterial infection.Type: GrantFiled: January 31, 2012Date of Patent: September 4, 2018Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMYInventor: Daniel Zurawski
-
Patent number: 10064859Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.Type: GrantFiled: August 24, 2015Date of Patent: September 4, 2018Assignee: ALKERMES PHARMA IRELAND LIMITEDInventors: Wilfredo Morales, Jr., Tarek A. Zeidan, Renato A. Chiarella, Steven G. Wright, Jason M. Perry
-
Patent number: 10064860Abstract: Methods for inhibiting the activity of Clostridium difficile in a subject comprises administering to the subject a pharmaceutical composition consisting of clofazimine and at least one pharmaceutically acceptable excipient. Pharmaceutical compositions consisting of clofazimine at least one pharmaceutically acceptable excipient are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.Type: GrantFiled: December 4, 2017Date of Patent: September 4, 2018Assignee: KamTek, Inc.Inventors: Venkata M. Reddy, Wolf Prensky, Sharanjit VedBrat
-
Patent number: 10064861Abstract: A compound of formula (I) is provided: wherein R1, R2, R3, R4, L and Z have the meaning given in the claims. Further provided is the prophylaxis and treatment of diseases with the compound of formula (I).Type: GrantFiled: November 30, 2016Date of Patent: September 4, 2018Assignee: Merck Patent GmbHInventors: Catherine Jorand-Lebrun, Santosh Kulkarni, Serge Christmann-Franck
-
Patent number: 10064862Abstract: Methods and compositions for preventing and/or treating viral infections are provided. The methods involve administering an agent that stabilizes or enhances Axin1 activity, e.g. and agent that inhibits tankyrase. Administration of the agent stimulates or increases interferon activity, thereby preventing or lessening at least one symptom of virus infection. The virus infection may be caused by a respiratory virus such as influenza vims.Type: GrantFiled: March 3, 2015Date of Patent: September 4, 2018Assignee: THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITYInventors: Lin Liu, Yujie Guo
-
Patent number: 10064863Abstract: Pharmaceutical compositions and single unit dosage forms of Compound A (3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione), or an enantiomer or a mixture of enantiomers thereof, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, are provided herein. Also provided are methods of treating, managing, or preventing cancer using the dosage forms described herein.Type: GrantFiled: August 26, 2016Date of Patent: September 4, 2018Assignee: Celgene CorporationInventors: Colin Walters, William Bowen, Yali Sun, Jay Brumfield, Xiaoxuan Shen, Daozhong Zou, Indrajit Ghosh
-
Patent number: 10064864Abstract: Disclosed are an anti-abnormal proliferation of angiogenesis compound represented by formula I, use and intermediate thereof. The compound has good effect against abnormal proliferation of angiogenesis, and the activity of the compound is produced by inhibiting VEGFR2. The compound can be used for treating diseases, such as wet macular degeneration, inflammation, malignant tumor and the like, caused by abnormity of angiogenesis and protein kinases such as VEGFR2, FGFR2 and the like.Type: GrantFiled: October 20, 2016Date of Patent: September 4, 2018Assignee: GUANGZHOU KANGRUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Rui Hou, Gen Li